GLORIA-AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients With Atrial Fibrillation (Phase I)

This study constitutes Phase I of the Registry Program. The main objective of this study is to characterize the newly diagnosed non-valvular AF patient population at risk for stroke and the selection of antithrombotic treatment for stroke prevention in a real-world setting before dabigatran etexilate is approved for the prevention of strokes and systemic emboli in patients with non-valvular AF in different regions of the world.

本研究为注册登记研究计划的第一阶段。本研究的核心目标为：在达比加群酯获批用于全球不同地区非瓣膜性心房颤动（non-valvular Atrial Fibrillation, 简称AF）患者的卒中及体循环栓塞预防前，于真实世界场景中，明确初诊的卒中风险非瓣膜性AF患者人群的特征，并确定适用于卒中预防的抗血栓治疗方案。